Marinus Pharmaceuticals (NASDAQ:MRNS) Raised to “Hold” at StockNews.com

StockNews.com upgraded shares of Marinus Pharmaceuticals (NASDAQ:MRNS) from a sell rating to a hold rating in a research report released on Monday.

Several other equities analysts also recently issued reports on the stock. Cantor Fitzgerald reissued an overweight rating and set a $13.00 price target on shares of Marinus Pharmaceuticals in a report on Monday. Truist Financial reissued a buy rating and set a $10.00 price target on shares of Marinus Pharmaceuticals in a report on Tuesday, June 18th. LADENBURG THALM/SH SH downgraded shares of Marinus Pharmaceuticals from a buy rating to a neutral rating in a research note on Wednesday, August 14th. Finally, HC Wainwright reaffirmed a buy rating and issued a $11.00 target price on shares of Marinus Pharmaceuticals in a research note on Wednesday, August 14th. Five equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of Hold and a consensus price target of $10.25.

Marinus Pharmaceuticals Price Performance

NASDAQ:MRNS opened at $1.39 on Monday. Marinus Pharmaceuticals has a 52 week low of $1.05 and a 52 week high of $11.26. The company has a market capitalization of $76.56 million, a price-to-earnings ratio of -0.53 and a beta of 1.13. The company has a 50-day moving average of $1.34 and a 200-day moving average of $3.22. The company has a debt-to-equity ratio of 5.68, a quick ratio of 2.15 and a current ratio of 2.28.

Marinus Pharmaceuticals (NASDAQ:MRNS) last announced its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.01). Marinus Pharmaceuticals had a negative net margin of 493.14% and a negative return on equity of 7,831.35%. The firm had revenue of $8.06 million for the quarter, compared to the consensus estimate of $9.05 million. During the same period in the prior year, the business earned ($0.61) earnings per share. As a group, equities research analysts anticipate that Marinus Pharmaceuticals will post -1.88 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Marinus Pharmaceuticals

Several institutional investors have recently modified their holdings of the business. Avoro Capital Advisors LLC grew its holdings in Marinus Pharmaceuticals by 31.4% during the first quarter. Avoro Capital Advisors LLC now owns 4,140,607 shares of the biopharmaceutical company’s stock valued at $37,431,000 after purchasing an additional 990,607 shares during the period. Acadian Asset Management LLC acquired a new position in Marinus Pharmaceuticals during the second quarter valued at approximately $813,000. Renaissance Technologies LLC acquired a new position in Marinus Pharmaceuticals during the second quarter valued at approximately $727,000. Superstring Capital Management LP acquired a new position in Marinus Pharmaceuticals during the fourth quarter valued at approximately $5,027,000. Finally, XTX Topco Ltd acquired a new position in Marinus Pharmaceuticals during the second quarter valued at approximately $232,000. Institutional investors and hedge funds own 98.80% of the company’s stock.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.